Phase II Study of Faslodex ® in Recurrent/Metastatic Endometrial Carcinoma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 22 Mar 2018
At a glance
- Drugs Fulvestrant (Primary)
- Indications Endometrial cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 03 Mar 2010 New source identified and integrated (Robert H. Lurie Comprehensive Cancer Center, Northwestern University record no. GOG0188).
- 26 Jan 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.